Nanofibre scale-up and industrial validation - Industrial Biotechnology Catalyst Translation and Industrial Research Awards

生物制药是制药业一个日益重要的部门，目前正在开发的所有药物中，超过三分之一是生物制药，它们占前十大收入大片的一半。开发一种新药通常需要10年以上的时间和8亿美元。全球对更便宜的生物疗法的需求推动了降低制造成本的需求。生物疗法是抗击癌症和神经退行性疾病等疾病的许多新工具。目前很大一部分成本来自现在用来确保这些治疗的安全性和有效性的净化技术。该项目旨在建立在拥有新型纳米纤维净化技术的中小企业Puridify和开发工业生物处理技术的世界领先研究机构伦敦大学学院(UCL)之间现有合作的基础上。该项目的成功获奖将见证创新生物处理平台技术的开发和商业化，从而实现各种现有产品和新产品的高性价比生产。该项目将加快Puridify的新型平台下游生物处理技术的开发，使其走向商业活动。提高生产率的技术将为新产品和现有产品提供一条有效的制造路线，通过降低成本和实现下一代生物疗法的经济制造，造福社会和整个行业。利用新的加工技术、理论和模型，这个综合工业研究和开发项目将通过将英国工业生物技术社区的关键学术和商业组成部分聚集在一起，加速这项技术的商业化。

Biopharmaceuticals are an increasingly important sector of the pharmaceutical industry, over one third of all drugs now in development are biopharmaceuticals and they make up half of the top 10 revenue blockbusters. It typically takes over 10 years and $800 million to develop a new drug. Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. This project aims to build on existing collaborations between Puridify, an SME with a novel nanofibre purification technology, and University College London (UCL), a world leading research organisation for the development of industrial bioprocessing technologies. The successful award of this project lead by Puridify and supported by shadow industrial partners will see the development and commercialisation of innovative bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new products.The project will accelerate development of Puridify's novel platform downstream bioprocessing technologies towards commercial activity. The technologies increased productivity will provide an efficient manufacturing route to both new and existing products benefiting society and the sector as a whole by reducing costs and enabling the economic manufacture of next generation biotherapeutics. Using new processing technologies, theory and modelling, this integrated Industrial Research and Development project will accelerate the commercialisation of this technology by bringing together key academic and business components of the UK Industrial Biotechnology community.